HEALTHIT.COM
Research
RESEARCH PREVIEW · 2026-08-27
Menu
2026-08-22Corti achieves ISO/IEC 270012026-08-22Geisinger case: 70% faster prior auth TAT2026-08-22Infinitus SOC 2 Type II compliance2026-08-22AKASA HITRUST/SOC 2 and 100% pre-bill review2026-08-22Infinitus 2025 recap: 1.17M patients automated2026-08-22HIPAA/SOC 2 Type II; recordings deleted2026-08-19Luma-PCC partnership to bring AI-enabled communications to 300+ pediatric practices2026-08-15Glass ranks top-tier on ARISE NOHARM clinical safety benchmark2026-08-15ISO 27001, HIPAA, 7+ FDA 510(k)s documented2026-08-15UpToDate integrated into Epic EHR/MyChart and ambient AI workflows2026-08-06UpToDate Expert AI adopted by ~2,500 U.S. hospitals and health systems2026-07-292.7M weekly interactions; US CAB launch2026-07-23Anterior-Stellarus partnership2026-07-23Strategic partnership with Stellarus to enable real-time AI-driven prior authorization for health plans2026-07-22Waystar Q2 2026 beat; AI anomaly detection traction2026-07-21Patient Pipeline: AI-powered new patient acquisition from ad spend to booked care2026-07-21Luma launches AI Patient Pipeline for new patient acquisition2026-07-07SMART on FHIR + Epic Toolbox integration2026-06-30Nature Health SAFEMOM study shows Ada improves health-seeking behavior on MomConnect2026-06-26Modality Partnership (NHS) rolls out Heidi across 53 sites in the UK's largest clinical deployment of ambient AI2026-06-26NHS Modality Partnership rollout2026-06-24Roche acquires PathAI for ~$1B to bolster AI-based diagnostic algorithms2026-06-24Assort Health raises $120M Series C at $1.2B valuation2026-06-15Thoreau Group signs $12B agreement to take control of Ensemble Health

Imaging & Diagnostic AI · Assurance Record

HeartFlow Analysis (FFRct)

HeartFlow · Outpatient/ambulatory cardiac imaging; hospital cardiology · Cloud SaaS analysis service; DICOM upload with results returned to site; AWS infrastructure

Decision summary

Suitable for
Cardiology departments, health systems, outpatient cardiac imaging centers, payers
Documentary gate
Failed
Scenario match
Matches this scenario — FDA-cleared imaging AI platforms
Comparability
Not yet comparable in this scenario
Decision readiness
HISTORICALResearch only
Documented evidence
2 of 4 evidence claims independently confirmed · confidence Low
Critical unknowns
No critical documentary gaps identified
Last independent review
2026-08-27
press releaseCompleted an upsized IPO on Nasdaq (HTFL) raising ~$364.2M in gross proceeds at $19/share; shares began trading Aug 8, 20252025-08-11

Exact claim. Completed an upsized IPO on Nasdaq (HTFL) raising ~$364.2M in gross proceeds at $19/share; shares began trading Aug 8, 2025

Source
ir.heartflow.com
Type
press release
Published
2025-08-11
Retrieved
2026-08-27
Verification
excerpt_matched
Confidence
not stated
Reviewer
healthit-gate-v1
Claim version
v1
Supports
market_durability
Score contribution
Feeds market durability

Vendor or press announcement. Verify material claims against primary filings or contracts.

Open ir.heartflow.com
regulatory filingHeartFlow Analysis (FFRct) cleared via 510(k) K213857 on Oct 14, 2022 as an AI-based coronary vascular physiologic simulation software devic2022-10-14

Exact claim. HeartFlow Analysis (FFRct) cleared via 510(k) K213857 on Oct 14, 2022 as an AI-based coronary vascular physiologic simulation software device (Class II, product code PJA)

Source
accessdata.fda.gov
Type
regulatory filing
Published
2022-10-14
Retrieved
2026-08-27
Verification
unverified
Confidence
not stated
Reviewer
healthit-gate-v1
Claim version
v1
Supports
evidence_strength
Score contribution
Feeds evidence strength

A regulatory listing confirms authorization status — not real-world effectiveness or economics.

Open accessdata.fda.gov
press releaseReceived FDA 510(k) clearance and launched the next-generation HeartFlow Plaque Analysis platform in September 20252025-09-22

Exact claim. Received FDA 510(k) clearance and launched the next-generation HeartFlow Plaque Analysis platform in September 2025

Source
ir.heartflow.com
Type
press release
Published
2025-09-22
Retrieved
2026-08-27
Verification
excerpt_matched
Confidence
not stated
Reviewer
healthit-gate-v1
Claim version
v1
Supports
evidence_strength
Score contribution
Feeds evidence strength

Vendor or press announcement. Verify material claims against primary filings or contracts.

Open ir.heartflow.com
peer reviewed studyPLATFORM trial (JACC 2015): in 584 patients with suspected coronary disease, FFRCT-guided care reduced mean total medical costs by 32% in th2015-12-01

Exact claim. PLATFORM trial (JACC 2015): in 584 patients with suspected coronary disease, FFRCT-guided care reduced mean total medical costs by 32% in the planned-invasive stratum versus usual care ($7,343 vs $10,734; p<0.0001) over 90-day follow-up.

Source
doi.org
Type
peer reviewed study
Published
2015-12-01
Retrieved
2026-08-27
Verification
unverified
Confidence
not stated
Reviewer
healthit-gate-v1
Claim version
v1
Supports
evidence_strength
Score contribution
Feeds evidence strength

Peer-reviewed. Check population, setting, and applicability to your workflow before generalizing.

Open doi.org

Verified provider experience is not yet publishable. Fewer than five independent provider organizations have contributed eligible reviews. Reviewer mode is off. Experience never changes documentary scoring, freshness, or rank.

Buyer lenses — evidence-backed bands (not a 0–100 rank)
Clinical · Moderate · missing deployment_traction, interoperability, economic_value
Operations · Thinner · missing deployment_traction, interoperability, economic_value
Security & Privacy · Moderate · missing deployment_traction, interoperability
IT & Interop · Moderate · missing deployment_traction, interoperability
Finance & Procurement · Thinner · missing deployment_traction, economic_value
Strategic · Thinner · missing deployment_traction, interoperability
Deployment, integration, data handling
Integration maturity
announcedAnnounced or documented integration; marketplace listing not confirmed.
EHR path
UNKNOWN
Why unknown

Why. No reliable source on file. The platform does not infer values from weak sources.

What would close it. A primary source or independent verification.

FHIR / API
UNKNOWN
Why unknown

Why. No reliable source on file. The platform does not infer values from weak sources.

What would close it. A primary source or independent verification.

SSO
UNKNOWN
Why unknown

Why. Single-sign-on support is not documented in vendor or marketplace materials on file.

What would close it. Vendor security documentation or marketplace listing mentioning SSO/SAML/OIDC.

PHI / BAA
PHI processed in HIPAA/HITRUST-compliant cloud; encryption at rest and in transit · BAA available
Security attestations
SOC 2 Type II, HITRUST, ISO/IEC 27001:2022, ISO 13485:2016, HIPAA
FDA status
UNKNOWN
Why unknown

Why. No FDA listing found for this product's functions in the tracked category.

What would close it. An FDA 510(k)/De Novo listing, or a clear statement that no regulated function is claimed.

Pricing
Not publicly listed (per-study pricing); CMS APC 5724 reimbursement ~$1,017 (CY2025) and reported UK list price ~£700/test in NICE documentation per FitGap
Technical provenance

snap_8a8a4c9bb810aee3 · 2026-08-27T04:05Z · build 6a9fe1b

Forecast calibration is not in the public snapshot — shown as UNKNOWN rather than read from SQLite.

Known limitations
  • Deployment traction is UNKNOWN.
    Why unknown

    Why. No reliable source on file. The platform does not infer values from weak sources.

    What would close it. A primary source or independent verification.

  • Interoperability is UNKNOWN.
    Why unknown

    Why. No reliable source on file. The platform does not infer values from weak sources.

    What would close it. A primary source or independent verification.

  • Economic value evidence is UNKNOWN.
    Why unknown

    Why. No independently verifiable ROI claim (peer-reviewed, audited case, or independent benchmark) is on file.

    What would close it. An audited implementation report or peer-reviewed study with payback/throughput numbers.

Next-gen Plaque Analysis FDA clearance
2025-09-22
FDA 510(k) clearance and launch of next-generation HeartFlow Plaque Analysis platform
2025-09-22
IPO raises $364.2M on Nasdaq (HTFL)
2025-08-11
FDA 510(k) K213857 for FFRct
2022-10-14
Know something we have wrong about HeartFlow Analysis (FFRct)?

Open to everyone — no account needed. This is a non-PHI service: never include patient identifiers.

We cannot action an evidence claim without something to check.